The physics of imaging became the physics of treatment.
Capacitive fields that map permittivity inside the brain and breast — and, applied at different parameters, selectively disrupt cancer cell division from outside the body. Wearable. No radiation. Over 5,000 patients.
Biological tissue satisfies the same physical condition as an industrial vessel: it is dielectric.
The ECVT framework rests on a physical fact: the medium being imaged holds and transmits capacitive fields in patterns that encode its internal structure. Biological tissue satisfies the same condition. The capacitance measurements taken at the boundary of a pressurised process vessel translate directly to measurements at the boundary of a body.
Real-time volumetric (4D) imaging of human brain activity using ECVT was first proposed — a helmet-shaped 32-channel sensor array, data acquisition system, and computer system for reconstruction and display of brain activity on the scalp and inside the brain. The ECVT system comprises the helmet-shaped capacitive sensor, 32-channel DAS, and PC for real-time reconstruction. Brain tumour detection using ECVT was later demonstrated — localising charge accumulation in tumour tissue in both hemispheres and producing 3D volumetric reconstructions of cerebellar structures. A healthy brain shows high, homogeneous cortical activity; abnormalities — tumours, epileptic foci, pressure changes — appear as localised low-activity regions. Validation of ECVT permittivity maps against MRI and biopsy confirmed that malignant and benign tissue are distinguishable through dielectric contrast alone.
Prolonged study of capacitive field interactions with living cells yielded a finding beyond imaging. At frequencies below 300 kHz, these fields interfere selectively with the mitotic spindle in rapidly dividing cells. The physical selectivity mechanism: the electrically charged protein structures that form the spindle during mitosis interact with the applied field in ways determined by the cell's membrane potential and division rate. Cancer cells — dividing faster, with altered membrane potentials — are preferentially disrupted. Normal tissue, dividing far more slowly, is largely unaffected. This mechanism was patented as ECCT in 2012.
How a capacitive field outside the body reaches cancer cells within it.
From laboratory cell lines to clinical populations.
The biological chain from capacitive field to cancer cell death has been validated at every level. Coskun's biophysics work established the physical mechanism — spindle protein interaction under sub-300 kHz fields — in cellular models. MCF-7 breast cancer cell line studies confirmed reduced proliferation in vitro. Murine in vivo studies showed inhibited tumour growth alongside changes in cytokine expression suggesting modulation of the tumour immune microenvironment.
Brain ECVT work demonstrated that the same 32-channel sensor that maps brain activity can detect tumour charge accumulation volumetrically — providing a radiation-free imaging platform that works alongside ECCT therapy. Clinical and oncology research partnerships extended the findings to over 5,000 patients across glioblastoma, breast, liver, and cervical cancers, alongside dosimetry work establishing field intensity measurement and frequency optimisation per cancer type.
Where the research has been applied.
From laboratory cell studies to wearable therapy across thousands of patients.
Brain ECVT Imaging
32-channel helmet sensor maps permittivity distribution within the brain volume in real time — cortical activity, intracranial activity, tumour localisation, and 3D cerebellar reconstruction. No radiation, no contrast agents.
Breast ECVT Imaging
Volumetric permittivity maps distinguishing malignant, benign, cyst, and normal tissue through dielectric contrast — confirmed against biopsy findings by Keserci. Correlates with PET-CT FDG uptake without radiation dose.
Glioblastoma
ECCT delivered via helmet garment. Warsito's initial clinical programme: stage-4 cases including complete remission. Akayama's Japan programme extended to broader patient cohorts.
Breast Cancer
MCF-7 proliferation reduction confirmed in vitro. Wearable garment format for home delivery. Murine in vivo results established the immune modulation context for clinical application.
Liver & Cervical Cancers
Conforming electrode garments adapted to each anatomical site. Kaplan's oncology research and Akayama's clinical programme cover these cancer types alongside glioblastoma and breast.
Neuroscience Research
ECVT brain research — executed movement, imagined movement, cortical mapping — extends the healthcare imaging platform into functional brain research and brain-computer interface applications.